RT Journal Article
SR Electronic
T1 The evidence for magnetic resonance imaging as an outcome measure in proof-of-concept rheumatoid arthritis studies.
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 2465
OP 2469
VO 32
IS 12
A1 Conaghan, Philip G
A1 McQueen, Fiona M
A1 Peterfy, Charles G
A1 Lassere, Marissa N D
A1 Ejbjerg, Bo
A1 Bird, Paul
A1 O'Connor, Philip J
A1 Haavardsholm, Espen
A1 Edmonds, John P
A1 Emery, Paul
A1 Genant, Harry K
A1 Ostergaard, Mikkel
A1 OMERACT 7 Special Interest Group
YR 2005
UL http://www.jrheum.org/content/32/12/2465.abstract
AB Magnetic resonance imaging (MRI) has now been used extensively in cross-sectional and observational studies as well as in controlled clinical trials to assess disease activity and joint damage in rheumatoid arthritis (RA). MRI measurements or scores for erosions, bone edema, and synovitis have been developed and validated by several groups. The OMERACT criteria require that outcome measures demonstrate adequate validity, discriminative power, and feasibility if they are to be useful in clinical trials. Specific performance targets for these criteria depend on the scientific, regulatory, logistical, and financial context of the study in question. We review the extent to which MRI assessments of joint erosion, bone edema, and synovitis fulfil these criteria, particularly as they relate to proof-of-concept RA clinical trials.